Which of the following is considered a caution for raloxifene?

• A. History of venous thromboembolism.
• B. Active pregnancy.
• C. Caution in immobility and severe liver disease.
• D. Osteoarthritis.

Answer: (C)

Raloxifene, a selective estrogen receptor modulator used to prevent osteoporosis in postmenopausal women, has safety cautions tied to factors that can amplify its risks, especially regarding blood clots and liver function. Immobility raises the risk of venous thromboembolism because blood can pool in the legs when someone isn’t moving, which, when combined with raloxifene’s own tendency to increase clot risk, makes this a notable precaution. Severe liver disease matters because raloxifene is processed by the liver; impaired liver function can alter how the drug is metabolized and increase potential adverse effects, so caution is warranted. In contrast, a history of venous thromboembolism is typically viewed as a contraindication rather than a cautious use, and active pregnancy is also contraindicated. Osteoarthritis doesn’t directly affect raloxifene’s safety profile. So immobility and severe liver disease are the cautions most relevant to prescribing this medication.